Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cytori Therapeutics, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Steve Lokness who wrote (162)	1/7/2008 2:20:31 AM
From: SnowShredder	Respond to of 251

They have an interesting platform based on bone marrow stem cells. From what I've seen, I think their science has a lot of potential, although will it be the best way to skin a cat?...the jury is still out. Personally, I think CYTX has a better method. Adipose stem cells are a couple of logs more abundant and you can harvest liters of fat as opposed to a limited amount of bone marrow. This in turn means that you might have to amplify the BMSC to get an effective dose. The amplification opens the door to some potential safety issues in the cells(eg. after x replications cells can become cancerous). As opposed to CYTX bedside application can be harvested and readministered to the patient in an hour(no amplification needed for an effective dose). Also coming from a random donor, there is potential for disease transmision, not just viral but also genetic. Not to mention that pricewise amplification of cells is expensive, with all the testing to make sure that the cells are potentially disease free, I'm not sure how they will be able to compete pricewise(1 dose for OSIR~10K while CYTX might be 2-5K but has a one time up front cost for the machine). Near term, I think there is plenty of room for both companies, as they are competing in different areas. The areas with overlap, I like CYTX more due to the above...with the effectiveness of each to be determined. They are definitely interesting and worth keeping an eye on, I like their near term potential more than STEM and GERN, but I just like CYTX's potential more, with plenty of room for both...bwdik? Do your own Due Diligence :) Best of Luck, SS